Please login to the form below

Not currently logged in
Email:
Password:

Novartis discontinues cancer trial

Novartis has discontinued a clinical trial programme for investigational cancer treatment ASA404, incurring impairment charges of $120m

Novartis has announced it has discontinued a clinical trial programme for investigational cancer treatment ASA404 (vadimezan) after interim results from a phase III study showed the drug was unlikely to meet its primary endpoint, failing to extend patient survival.

The decision to end the programme means the Swiss company will face impairment charges of $120m to be taken in the fourth quarter of 2010. An impairment charge is a decrease in the value of a company based on inflated previous estimates regarding a company's intangible assets.

Novartis has already been hit by impairment charges in 2010, with the company facing costs of $590m when it discontinued the development of investigational compounds Mycograb (efungumab) and albinterferon alfa-2b.

Research into ASA404 was halted following a recommendation from an independent data monitoring committee to end the phase III trial, ATTRACT-2, ahead of schedule.

The trial was designed to investigate if the treatment significantly extended overall survival in patients with advanced non-small cell lung cancer (NSCLC) when used in combination with chemotherapy.

ASA404 had previously failed to meet the primary endpoint of ATTRACT-1 trial. This study evaluated the drug in combination with paclitaxel and carboplatin as first-line treatment for advanced NSCLC.

11th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics